These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 33171303

  • 21. Dissecting vancomycin-intermediate resistance in staphylococcus aureus using genome-wide association.
    Alam MT, Petit RA, Crispell EK, Thornton TA, Conneely KN, Jiang Y, Satola SW, Read TD.
    Genome Biol Evol; 2014 Apr 30; 6(5):1174-85. PubMed ID: 24787619
    [Abstract] [Full Text] [Related]

  • 22. Generation of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS.
    Berscheid A, François P, Strittmatter A, Gottschalk G, Schrenzel J, Sass P, Bierbaum G.
    J Antimicrob Chemother; 2014 Dec 30; 69(12):3190-8. PubMed ID: 25103491
    [Abstract] [Full Text] [Related]

  • 23. Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus.
    Vidaillac C, Gardete S, Tewhey R, Sakoulas G, Kaatz GW, Rose WE, Tomasz A, Rybak MJ.
    J Infect Dis; 2013 Jul 30; 208(1):67-74. PubMed ID: 23539745
    [Abstract] [Full Text] [Related]

  • 24. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA.
    Howden BP, Peleg AY, Stinear TP.
    Infect Genet Evol; 2014 Jan 30; 21():575-82. PubMed ID: 23567819
    [Abstract] [Full Text] [Related]

  • 25. Novel Mutation Sites in the Development of Vancomycin- Intermediate Resistance in Staphylococcus aureus.
    Wang Y, Li X, Jiang L, Han W, Xie X, Jin Y, He X, Wu R.
    Front Microbiol; 2016 Jan 30; 7():2163. PubMed ID: 28119680
    [Abstract] [Full Text] [Related]

  • 26. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.
    Shoji M, Cui L, Iizuka R, Komoto A, Neoh HM, Watanabe Y, Hishinuma T, Hiramatsu K.
    Antimicrob Agents Chemother; 2011 Aug 30; 55(8):3870-81. PubMed ID: 21628539
    [Abstract] [Full Text] [Related]

  • 27. Vancomycin susceptibility in methicillin-resistant Staphylococcus aureus is mediated by YycHI activation of the WalRK essential two-component regulatory system.
    Cameron DR, Jiang JH, Kostoulias X, Foxwell DJ, Peleg AY.
    Sci Rep; 2016 Sep 07; 6():30823. PubMed ID: 27600558
    [Abstract] [Full Text] [Related]

  • 28. Evolution of Daptomycin Resistance in Coagulase-Negative Staphylococci Involves Mutations of the Essential Two-Component Regulator WalKR.
    Jiang JH, Dexter C, Cameron DR, Monk IR, Baines SL, Abbott IJ, Spelman DW, Kostoulias X, Nethercott C, Howden BP, Peleg AY.
    Antimicrob Agents Chemother; 2019 Mar 07; 63(3):. PubMed ID: 30617095
    [Abstract] [Full Text] [Related]

  • 29. Adaptive laboratory evolution and independent component analysis disentangle complex vancomycin adaptation trajectories.
    Fait A, Seif Y, Mikkelsen K, Poudel S, Wells JM, Palsson BO, Ingmer H.
    Proc Natl Acad Sci U S A; 2022 Jul 26; 119(30):e2118262119. PubMed ID: 35858453
    [Abstract] [Full Text] [Related]

  • 30. WalK(S221P), a naturally occurring mutation, confers vancomycin resistance in VISA strain XN108.
    Peng H, Hu Q, Shang W, Yuan J, Zhang X, Liu H, Zheng Y, Hu Z, Yang Y, Tan L, Li S, Hu X, Li M, Rao X.
    J Antimicrob Chemother; 2017 Apr 01; 72(4):1006-1013. PubMed ID: 27999059
    [Abstract] [Full Text] [Related]

  • 31. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.
    Matsuo M, Cui L, Kim J, Hiramatsu K.
    Antimicrob Agents Chemother; 2013 Dec 01; 57(12):5843-53. PubMed ID: 24018261
    [Abstract] [Full Text] [Related]

  • 32. New insights into the WalK/WalR (YycG/YycF) essential signal transduction pathway reveal a major role in controlling cell wall metabolism and biofilm formation in Staphylococcus aureus.
    Dubrac S, Boneca IG, Poupel O, Msadek T.
    J Bacteriol; 2007 Nov 01; 189(22):8257-69. PubMed ID: 17827301
    [Abstract] [Full Text] [Related]

  • 33. Impact of mutations in hVISA isolates on decreased susceptibility to vancomycin, through population analyses profile - area under curve (PAP-AUC).
    Silveira ACO, Caierão J, Silva CI, Anzai EK, McCulloch JA, d'Azevedo PA, Sincero TCM.
    Diagn Microbiol Infect Dis; 2019 Nov 01; 95(3):114854. PubMed ID: 31366440
    [Abstract] [Full Text] [Related]

  • 34. IS256-Mediated Overexpression of the WalKR Two-Component System Regulon Contributes to Reduced Vancomycin Susceptibility in a Staphylococcus aureus Clinical Isolate.
    Kuroda M, Sekizuka T, Matsui H, Ohsuga J, Ohshima T, Hanaki H.
    Front Microbiol; 2019 Nov 01; 10():1882. PubMed ID: 31474962
    [Abstract] [Full Text] [Related]

  • 35. Reconstruction of the Vancomycin-Susceptible Staphylococcus aureus Phenotype From a Vancomycin-Intermediate S. aureus XN108.
    Peng H, Rao Y, Yuan W, Zheng Y, Shang W, Hu Z, Yang Y, Tan L, Xiong K, Li S, Zhu J, Hu X, Hu Q, Rao X.
    Front Microbiol; 2018 Nov 01; 9():2955. PubMed ID: 30546356
    [Abstract] [Full Text] [Related]

  • 36. VraR Binding to the Promoter Region of agr Inhibits Its Function in Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA.
    Dai Y, Chang W, Zhao C, Peng J, Xu L, Lu H, Zhou S, Ma X.
    Antimicrob Agents Chemother; 2017 May 01; 61(5):. PubMed ID: 28289032
    [Abstract] [Full Text] [Related]

  • 37. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
    Neoh HM, Cui L, Yuzawa H, Takeuchi F, Matsuo M, Hiramatsu K.
    Antimicrob Agents Chemother; 2008 Jan 01; 52(1):45-53. PubMed ID: 17954695
    [Abstract] [Full Text] [Related]

  • 38. Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Roch M, Clair P, Renzoni A, Reverdy ME, Dauwalder O, Bes M, Martra A, Freydière AM, Laurent F, Reix P, Dumitrescu O, Vandenesch F.
    Antimicrob Agents Chemother; 2014 Sep 01; 58(9):5306-14. PubMed ID: 24957836
    [Abstract] [Full Text] [Related]

  • 39. Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing.
    Chen CJ, Lin MH, Shu JC, Lu JJ.
    J Antimicrob Chemother; 2014 Feb 01; 69(2):349-54. PubMed ID: 24092658
    [Abstract] [Full Text] [Related]

  • 40. Effect of genetic background on the evolution of Vancomycin-Intermediate Staphylococcus aureus (VISA).
    Su M, Davis MH, Peterson J, Solis-Lemus C, Satola SW, Read TD.
    PeerJ; 2021 Feb 01; 9():e11764. PubMed ID: 34306830
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.